Cullinan Therapeutics (CGEM) Projected to Post Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) is projected to post its quarterly earnings results before the market opens on Thursday, March 13th. Analysts expect Cullinan Therapeutics to post earnings of ($0.83) per share for the quarter.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.02. On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Stock Up 2.4 %

Shares of CGEM traded up $0.20 during trading hours on Friday, hitting $8.71. The company had a trading volume of 437,813 shares, compared to its average volume of 461,034. The firm has a market cap of $509.65 million, a P/E ratio of -3.07 and a beta of -0.12. The stock's 50 day moving average price is $10.14 and its 200 day moving average price is $13.62. Cullinan Therapeutics has a 52-week low of $7.90 and a 52-week high of $30.19.

Analyst Ratings Changes

Several research firms have recently commented on CGEM. HC Wainwright reiterated a "buy" rating and issued a $33.00 price objective on shares of Cullinan Therapeutics in a report on Friday, February 28th. Morgan Stanley reiterated an "overweight" rating and issued a $35.00 price objective (down previously from $38.00) on shares of Cullinan Therapeutics in a report on Friday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Cullinan Therapeutics presently has an average rating of "Buy" and a consensus price target of $32.86.

Remove Ads

Insider Buying and Selling

In other Cullinan Therapeutics news, insider Jeffrey Alan Jones sold 4,895 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $8.53, for a total transaction of $41,754.35. Following the sale, the insider now directly owns 174,164 shares of the company's stock, valued at approximately $1,485,618.92. The trade was a 2.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Nadim Ahmed sold 12,529 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $8.53, for a total value of $106,872.37. Following the sale, the chief executive officer now directly owns 430,621 shares in the company, valued at approximately $3,673,197.13. The trade was a 2.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,006 shares of company stock valued at $395,604 over the last ninety days. 6.07% of the stock is owned by insiders.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.